AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- Cancer vaccine development involves breaking immune tolerance to malignant cells.
"Exploiting a naturally occurring defense system, the immunotherapeutic approach embodies an ideal nontoxic treatment for cancer. Despite the evidence that immune effectors can play a significant role in controlling tumor growth either in natural conditions or in response to therapeutic manipulation, the cascade of molecular events leading to tumor rejection by the immune system remains to be fully elucidated. Nevertheless, some recent tumor immunology advancements might drastically change the way to design the next generation of cancer vaccines, hopefully improving the effectiveness of this therapeutic approach," investigators in Italy report.
"In the present work, we will focus on three main areas of particular interest for the development of novel vaccination strategies: cellular or molecular mechanisms of immune tolerance to malignant cells; synergism between innate and adaptive immune response; and tumor-immune system ...
Source: HighBeam Research, Cancer vaccines must break immune tolerance to malignant cells.